The strong financial case for regenerative medicine and the regen industry

Regenerative Medicine

Volumn 3, Issue 3, 2008, Pages 351-363

  Mason, Chris ^a   Dunnill, Peter ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Chronic disease; Costs; Finance; QALY; Regen; Regenerative medicine; US healthcare

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; ARTIFICIAL HEART PACEMAKER; ASSISTIVE TECHNOLOGY; BIOTECHNOLOGY; BRAIN DEPTH STIMULATION; CELL REGENERATION; CELL THERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; COUNSELING; DIALYSIS; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH INSURANCE; HEART FAILURE; HEMATOPOIETIC STEM CELL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIFE EXPECTANCY; NONHUMAN; ORGANOGENESIS; PARKINSON DISEASE; PATIENT CARE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; REGENERATIVE MEDICINE; REVASCULARIZATION; SAFETY; SMOKING CESSATION; SPINAL CORD INJURY; STROKE; TOTAL HIP PROSTHESIS; UNITED STATES; CELL TRANSPLANTATION; DRUG INDUSTRY; ECONOMICS; HEALTH CARE POLICY; HEALTH ECONOMICS; INDUSTRY; METHODOLOGY; ORGANIZATION AND MANAGEMENT; PHARMACOECONOMICS; QUALITY CONTROL; TREATMENT OUTCOME;

CELL TRANSPLANTATION; DRUG INDUSTRY; ECONOMICS, MEDICAL; ECONOMICS, PHARMACEUTICAL; HEALTH CARE COSTS; HEALTH CARE REFORM; HUMANS; INDUSTRY; INSURANCE, HEALTH; PRIVATE SECTOR; PUBLIC SECTOR; QUALITY CONTROL; REGENERATIVE MEDICINE; TREATMENT OUTCOME;

EID: 48849099450     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460751.3.3.351     Document Type: Article

References (62)

1. Pisano GP: Can Science be a Business? Harvard Business Review, USA 84, 1-13 (2006).
2. Mason C, Dunnill P: Lessons for the nascent regenerative medicine industry from the biotech sector. Regen. Med. 2, 753-756 (2007).
3. Mason C, Dunnill P: A brief definition of regenerative medicine. Regen. Med. 3, 1-5 (2008).
4. Sugaya K, Kwak YD, Ohmitsu O, Marutle A, Greig NH, Choumrina E: Practical issues in stem cell therapy for Alzheimer's disease. Curr. Alzheimer Res. 4, 370-377 (2007).
5. Oliveira AA Jr, Hodges HM: Alzheimer's disease and neural transplantation as prospective cell therapy. Curr. Alzhelmer Res. 2, 79-95 (2005).
6. Yamasaki TR, Blurton-Jones M, Morrissette DA, Kitazawa M, Oddo S, LaFeria FM: Neural stem cells improve memory in an inducible mouse model of neuronal loss. J. Neurosci. 27 (44), 11925-11993 (2007).
7. Brodie JC, Humes HD: Stem cell approaches for the treatment of renal failure. Pharmacol. Rev. 57 (3), 299-313 (2005).
8. Huse DM, Schulman K, Orsini L, Castelli-Haley J, Kennedy S, Lenhart C: Burden of illness in Parkinson's disease. Mov. Disord. 20, 1449-1454 (2005).
9. National Spinal Cord Injury Statistical Centre. Spinal cord injury facts and figures at a glance. University of Alabama, Birmingham, AL, USA 2006.
10. Brown G: The Bitter End. New Scientist 196(2625), 42-43 (2007).
11. Takahashi K, Tanabe K, Ohnuki M et al.: Induction of pluripatent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872 (2007).
12. Yu J, Vodyanik MA, Smuga-Otto K et al.: Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917-1920 (2007).
13. Rosenzweig A: Cardiac cell therapy - mixed results from mixed cells. N. Engl. J. Med. 355, 1274-1277 (2006).
14. Burt RK, Loh Y, Pearce W et al.: Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA 299, 925-936 (2008).
15. Laflamme MA, Chen KY, Fugate JA, Naumova AV, Muskheli V: Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat heart. Nat. Biotechnol. 25, 1015-1024 (2007).
16. Kellar RS, Shepherd R, Larson DF, Naughton GK, Williams SK: Carchac patch constructed from human fibroblasts attenuates reduction in cardiac function after acute infarct. Tissue Eng. 11, 1678-1687 (2005).
17. Shapiro AMJ, Ricordi C, Hering B et al.: International trial of the Edmonton protocol for islet transplantation. N. Engl. J. Med. 355, 1318-1330 (2006).
18. Kroon E, Martinson LA, Kadoya K et al.: Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat. Biotechnol. 26(4), 443-452 (2008).
19. Bang OY, Lee JS, Lee H, Lee G: Autologous mesenchyonal cell transportation in stroke patients. Ann. Neurol. 57, 874-882 (2005).
20. Kondziolka D, Steinberg GK, Wechsler L et al.: Neurotransplantation for patients with subcorticol motor stroke: a Phase II randomized trial. J. Neurosurgery 103, 38-45 (2005).
21. Bjorklund A: Cell therapy for Parkinsonn's disease: problems and prospects. Stem cells: nuclear reprogramming and therapeutic applications. Novartis Foundation Symposium 265, 174-187 (2005).
22. Gordon PH, Yu Q, Qualls C et al.: Reaction time and movement time after embryonic cell implantation in Parkinson disease. Arch. Neurol. 61, 858-861 (2004).
23. Stover NP, Bakay RA, Subramanian T et al.: Intrastriatal implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson disease. Arch. Neurol. 62, 1833-1837 (2005).
24. Li Y, Decherchi P, Raisman G: Transplantation of olfactory ensheathing cells in spinal cord lesions restores breathing and climbing. J. Neurosci. 23, 727-731 (2003).
25. Feron F, Perry C, Cochrane J et al.: Autologous olfactory ensheathing cell transplantation in human spinal cord injury. Brain 128, 2951-2960 (2005).
26. Lima C, Pratas-Vital J, Escada P, Hasse-Ferreira A, Capucho C, Peduzzi JD: Olfactory mucosa autografts in human spinal cord injury: a pilot clinical study. J. Spinal Cord Med. 29, 191-203 (2006).
27. Cloutier F, Siegenthaler MM, Nistor G, Keirstead HS: Transplantation of human embryonic stern cell-derived oligodendrocyte progenitors into rat spinal cord injuries does not cause harm. Regen. Med. 1, 469-479 (2006).
28. Boiland BJ, Tilley S, New AM, Dunlop DG, Oreffo RO: Adult mesenchymal stem cells and impaction grafting: a new clinical paradigm shift. Expert Rev. Med. Devices 4, 393-404 (2007).
29. Hoos A, Parmiani G, Hege K: A clinical development paradigm for cancer vaccines and related biologics. J. Immunother. 30, 1-15 (2007).
30. Dalerba P, Cho RW, Clarke MF: Cancer stem cells: models and concepts. Annu. Rev. Med. 58, 267-284 (2007).
31. BitMansour A, Cao TM, Chao S, Shashidhar S, Brown JM: Single infusion of myeloid progenitors reduces death from Aspergillus fumigatus following chemotherapy-induced neutropenia. Blood 105, 3535-3537 (2005).
32. Friedman DS, O'Colmain BJ, Munoz B et al.: Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 122, 564-565 (2004).
33. Brown MM, Brown GC, Stein JD, Roth Z et al.: Age-related macular degeneration: economic burden and value-based medicine analysis. Can. J. Opthalmol. 40, 277-287 (2005).
34. Vugler A, Lawrence J, Walsh J et al.: Embryonic stem cells and retinal repair. Mech. Dev. 124, 807-829 (2007)
35. Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K: The burden and costs of chronic diseases in low-income and middle-income countries. Lancet 370, 1929-1938 (2007).
36. Greenwood HL, Singer PA, Downey GP, Martin DK, Thorsteinsdottir H: Regenerative medicine and the developing world. PLoS Med. 3, e381 (2006).
37. Panepinto JA, Walters MC, Carreras J: Non-Malignant Marrow Disorders Working Committee, Center for International Blood and Marrow Transplant Research. Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. Br. J. Haematol. 137(5), 479-485 (2007).
38. Baker L, Deal B: Economic impact analysis: Proposition 71 California stem cell research and cures initiative (2004).
39. Longaker MT, Baker LC, Greely HT: Proposition 71 and CIRM - assessing the return on investment. Nat. Biotechnol. 25, 513-521 (2007).
40. Gold MR, Stevenson D, Fryback DG: HALYS and QALYS and DALYS, oh my: similarities and differences in summary measures of population health. Annu. Rev. Public Health 23, 115-134 (2002).
41. Remak E, Hutton J, Jones M, Zagari M: Changes in cost-effectiveness over time: the case of epoetin-α for renal replacement therapy patients in the UK. Eur. J. Health Econom. 4, 115-123 (2003).
42. Williams A: Economics of coronary artery bypass grafting. Br. Med. J. 291, 326-329 (1985).
43. Mitton CR, Rose MS, Koshman ML, Sheldon RS: Cost-utility analysis of pacemakers for the treatment of vasovagal syncope. Am. J. Cardiol. 84, 1356-1358 (1999).
44. Redekop WK, McDonnell J, Verboom P, Lovas K, Kalo Z: The cost-effectiveness of Apligraf treatment of diabetic foot ulcers. Pharmacoeconomics 21, 1171-1183 (2003).
45. Prosser LA, Stinnett AA, Goldman PA: Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann. Intern. Med. 132, 769-779 (2000).
46. Drexler H, Fuchs M: Current limitations in treatment of heart failure: new avenues and treatment options. J. Cardiovasc. Electrophysiol. 13(Suppl. 1), S53-S56 (2002).
47. Atala A, Bauer S, Soker S, JJ, Retik AB: Tissue-engineered autologous bladders for patients needing cystoplasty. Lancet 367, 1241-1246 (2006).
48. De Bie C: Genzyme: 15 years of cell and gene therapy research. Regen. Med. 2, 95-97 (2007).
49. Mason C, Hoare M: Regenerative medicine bioprocessing: building a conceptual framework based on early studies. Tissue Eng. 13, 301-311 (2007).
50. Pollock A: Pricing pills by results. The New York Times, 14th July (2007).
51. Kemp P: History of regenerative medicine: looking backwards to move forwards. Regen. Med. 1, 653-669 (2005).
52. Araujo DV, Tavares LR, Verissimo R, Ferraz MB, Mequita T: Cost of heart failure in the United Health System. Arg. Bras. Cardiol. 84, 422-427 (2005).
53. Leese B: The cost of diabetes and its complications. Soc. Sci. Med. 10, 1303-1310 (1992).
54. Sennfait K, Magnusson M, Carlsson P: Comparison of haemodialysis and peritoneal dialysis - a cost-utility analysis. Perit. Dial. Int. 22, 39-47 (2002).
55. Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T: Cost - effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. J. Am. Med. Assoc. 278, 1759-1766 (1997).
56. O'Shea K, Bale E, Murray P: Cost analysis of primary total hip replacement. Ir. Med. J. 95(6), 177-180 (2002).
57. Minas T: Chondrocyte implantation in the repair of chondral lesions of the knee: economics and quality of life. Am. J. Orthop. 27, 739-744 (1998).
58. Sollano A Rose EA, Williams DL et al.: Cost-effectiveness of coronary artery bypass surgery in octogenarians. Ann. Surg. 228, 297-306 (1998).
59. Tomaszewski KJ, Holloway RG: Deep brain stimulation in the treatment of Parkinson's disease: a cost-effectiveness analysis. Neurology 57, 663-671 (2001).
60. van Hout B, Bonsel G, Habbema D, van der Maas P, de Charro F: Heart transplantation in the Netherlands; costs, effects and scenarios. J. Health Econ. 12. 73-93 (1993).
61. Jassal SV, Krahn MD, Naglie G et al.: Kidney transplantation in the elderly: a decision analysis. J. Am. Soc. Nephrol. 14, 187-196 (2003).
62. Clegg AJ, Scott DA, Loveman E, Colquitt JL, Royle P, Bryant J: Clinical and cost-effectiveness of left ventricular assist devices as a bridge to heart transplantation for people with end-stage heart failure: a systemic review and economic evaluation. Eur. Heart J. 27, 2929-2938 (2005).